Illumina (NASDAQ:ILMN) witnessed a selling pressure and the shares last traded with a loss of -0.05 points or -0.04% at $136.29. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $21.4 million with an inflow of $32.27 million in upticks and an outflow of $10.87 million in downticks. Using the data, the up/down ratio is found to be 2.97. The share price has recorded -3.76% on a weekly basis.A block trade of $19.23 million in uptick and $0 million in downtick was also observed, resulting in an up/down ratio of 0. The net money flow of the block trade stood at a $19.23, signaling heavy buying.
Illumina Inc. has lost 3.23% in the last five trading days and dropped 2.27% in the last 4 weeks. Illumina Inc. has dropped 8.78% during the last 3-month period . Year-to-Date the stock performance stands at -28.6%.
Currently the company Insiders own 1.6% of Illumina shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.59% . Institutional Investors own 98.52% of Illumina shares. During last six month period, the net percent change held by insiders has seen a change of -6.78%. . On the companys insider trading activities,The director of Illumina Inc, Bowman A Blaine sold 5,000 shares at $135.17 on June 16, 2016. The Insider selling transaction had a total value worth of $675,850. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Illumina (NASDAQ:ILMN) rose 0.52% or 0.71 points on Friday and made its way into the gainers of the day. After trading began at $136.36 the stock was seen hitting $138.58 as a peak level and $135.615 as the lowest level. The stock ended up at $137.05. The daily volume was measured at 1,780,630 shares. The 52-week high of the share price is $242.37 and the 52-week low is $127.1. The company has a market cap of $20,174 million.
Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.